ATE513561T1 - Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien - Google Patents

Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien

Info

Publication number
ATE513561T1
ATE513561T1 AT06808431T AT06808431T ATE513561T1 AT E513561 T1 ATE513561 T1 AT E513561T1 AT 06808431 T AT06808431 T AT 06808431T AT 06808431 T AT06808431 T AT 06808431T AT E513561 T1 ATE513561 T1 AT E513561T1
Authority
AT
Austria
Prior art keywords
adjuvants
alteration
clip
balance
flu vaccines
Prior art date
Application number
AT06808431T
Other languages
English (en)
Inventor
Derek O'hagan
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37897441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE513561(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of ATE513561T1 publication Critical patent/ATE513561T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06808431T 2005-11-04 2006-11-06 Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien ATE513561T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US73402605P 2005-11-04 2005-11-04
US81247506P 2006-06-08 2006-06-08
PCT/GB2006/004136 WO2007052059A2 (en) 2005-11-04 2006-11-06 Changing th1/th2 balance in split influenza vaccines with adjuvants

Publications (1)

Publication Number Publication Date
ATE513561T1 true ATE513561T1 (de) 2011-07-15

Family

ID=37897441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06808431T ATE513561T1 (de) 2005-11-04 2006-11-06 Veränderung des th1/th2-gleichgewichts in spalt- grippeimpfstoffen mit adjuvantien

Country Status (12)

Country Link
US (1) US20090047353A1 (de)
EP (1) EP1951300B1 (de)
JP (1) JP5363107B2 (de)
AT (1) ATE513561T1 (de)
AU (1) AU2006310340B2 (de)
CA (1) CA2628397C (de)
CY (1) CY1112895T1 (de)
DK (1) DK1951300T3 (de)
NZ (1) NZ568212A (de)
PL (1) PL1951300T3 (de)
PT (1) PT1951300E (de)
WO (1) WO2007052059A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1945252T3 (pl) * 2005-11-04 2013-11-29 Seqirus Uk Ltd Szczepionki zawierające oczyszczone antygeny powierzchniowe otrzymane z wirusów grypy hodowanych w hodowli komórkowej i skwalen jako adiuwant
EP2014279A1 (de) * 2007-06-22 2009-01-14 Pevion Biotech AG Virosomen enthaltend Haemagglutinin, das von über Zelllinien hergestellten Influenza-Viren stammt, Zusammensetzungen, Herstellungsverfahren, Verwendung davon
ES2535101T3 (es) 2008-03-18 2015-05-05 Novartis Ag Mejoras en la preparación de antígenos en vacuna de virus de la gripe
EP2396032B1 (de) 2009-02-10 2016-09-28 Seqirus UK Limited Influenza-impfstoffe mit reduzierten squalen-mengen
EP2207031A1 (de) * 2009-05-18 2010-07-14 Abbott Biologicals B.V. Hilfsstoffprüfung für Impfstoffzubereitungen
CN105125488A (zh) * 2010-05-12 2015-12-09 诺华股份有限公司 制备鲨烯的改良方法
CA3007787C (en) 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
GB201009273D0 (en) * 2010-06-03 2010-07-21 Glaxosmithkline Biolog Sa Novel vaccine
US9821051B1 (en) 2010-10-28 2017-11-21 Seqirus UK Limited Reducing hospitalization in elderly influenza vaccine recipients
CA2879570A1 (en) 2012-07-24 2014-01-30 Pharmacyclics, Inc. Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
PE20151604A1 (es) 2012-11-02 2015-11-04 Pharmacyclics Llc Terapia adyuvante con inhibidores de quinasa de la familia tec
EP3119910A4 (de) 2014-03-20 2018-02-21 Pharmacyclics LLC Phospholipase c gamma 2 und resistenzassoziierte mutationen
WO2016001907A1 (en) * 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2019086463A1 (en) 2017-10-30 2019-05-09 Baxalta GmbH Environmentally compatible detergents for inactivation of lipid-enveloped viruses

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1124013A (zh) * 1993-02-19 1996-06-05 史密丝克莱恩比彻姆公司 含3-邻位-脱酰基的单磷酰基脂质a的流感疫苗组合物
ES2370937T3 (es) * 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
WO1999027961A1 (en) * 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
CA2363141C (en) * 1999-02-26 2010-04-06 Novartis Vaccines And Diagnostics, Inc. Microemulsions with adsorbed macromolecules and microparticles
CN1227030C (zh) * 1999-04-19 2005-11-16 史密丝克莱恩比彻姆生物有限公司 包含皂甙和免疫刺激寡核苷酸的佐剂组合物
GB9923176D0 (en) 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US20040109874A1 (en) * 1999-11-10 2004-06-10 Powderject Vaccines, Inc. Induction of mucosal immunity by vaccination via the skin route
JP2004508290A (ja) * 2000-04-26 2004-03-18 バイオベクター　セラピューティクス 免疫調節における粒状ベクターの使用
CN100489107C (zh) * 2000-04-28 2009-05-20 圣朱德儿童研究医院 用于产生感染性流感病毒的dna转染系统
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
JP4675317B2 (ja) * 2003-01-30 2011-04-20 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アジュバント化インフルエンザワクチン
CN101214375B (zh) * 2003-03-24 2011-04-06 英特塞尔股份公司 改进的疫苗
EP1755666B1 (de) * 2004-05-28 2010-12-15 GlaxoSmithKline Biologicals SA Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
US20070292386A9 (en) * 2004-12-02 2007-12-20 Campbell Robert L Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
TW200700079A (en) 2005-03-23 2007-01-01 Glaxosmithkline Biolog Sa Composition

Also Published As

Publication number Publication date
WO2007052059A3 (en) 2007-08-30
NZ568212A (en) 2012-03-30
CA2628397C (en) 2013-08-20
EP1951300B1 (de) 2011-06-22
JP5363107B2 (ja) 2013-12-11
DK1951300T3 (da) 2011-10-03
JP2009514842A (ja) 2009-04-09
CA2628397A1 (en) 2007-05-10
CY1112895T1 (el) 2016-04-13
WO2007052059A2 (en) 2007-05-10
PL1951300T3 (pl) 2012-03-30
AU2006310340A1 (en) 2007-05-10
US20090047353A1 (en) 2009-02-19
AU2006310340B2 (en) 2011-02-10
EP1951300A2 (de) 2008-08-06
PT1951300E (pt) 2011-09-05

Similar Documents

Publication Publication Date Title
CY1112895T1 (el) Μεταβολη της ισορροπιας τη1/τη2 στα διαχωρισμενα αντιγριπικα εμβολια με ανοσοενισχυτικα
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
NO20054608L (no) Influensavirusvaksine
DK2468300T3 (da) Vaccinesammensætning indeholdende syntetisk adjuvant
EA200801756A1 (ru) Противогриппозные вакцины, содержащие гемагглютинин и белки матрикса
DK1951299T3 (da) Influenzavacciner indeholdende kombinationer af partikelformige adjuvanser og immunforstærkere
ATE491467T1 (de) Impfstoffzusammensetzungen mit virosomen und einem saponin-adjuvans
EA200900784A1 (ru) Вакцины, включающие антиген из четырех штаммов вируса гриппа
NO20023829L (no) Proteosom influensavaksine
WO2007095320A3 (en) Hpv antigens, vaccine compositions, and related methods
ATE426412T1 (de) Adjuvante influenza-vakzine
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
EA200970271A1 (ru) Получение вакцин против вируса гриппа без использования куриных эмбрионов
EA200801798A1 (ru) Виросомоподобные везикулы, содержащие антигены, производные от gp41
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
EA201391515A1 (ru) Инактивированная вакцина вируса денге
AR060565A1 (es) Vacuna para la gripe aviaria y metodos de uso
EA201891124A2 (ru) Новые мукозные адъюванты и системы доставки
CL2006000880A1 (es) Composicion inmunogena para causar una respuesta inmunologica contra una especie helicobacter y circovirus porcino que comprende antigenos de dichos patogenos; metodo para inducir una respuesta inmunologica contra dichos patogenos; kit para preparar la composicion inmunogena.
WO2008134643A3 (en) Trypanosoma antigens, vaccine compositions, and related methods
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
EA200801250A1 (ru) Эмульсии, содержащие свободное поверхностно-активное вещество в водной фазе, в качестве адъюванта сплит вакцин против гриппа
CL2011002994A1 (es) Construccion de proteina que comprende polipeptido casb7439; composicion inmunogenica que comprende dicha construccion; uso de la composicion porque sirve para inducir respuesta inmunitaria al casb7439 en un animal.
EA201400216A1 (ru) Консервирование биологических продуктов, в частности вакцин, с применением вакуума
ATE419008T1 (de) Adjuvante zusammensetzung und anwendungsverfahren dafür

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1951300

Country of ref document: EP